GSK Bolsters Respiratory and Vaccine Portfolio with Key Regulatory Wins and Product Launches
GSK secures European approval to expand the use of its RSV vaccine Arexvy to a broader adult population, while launching a new long-acting biologic for severe asthma in the U.S. These strategic moves reinforce the company's focus on high-growth areas in vaccines and respiratory therapies.